Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernesto Rossi

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Recenti Progressi in Medicina|December 28, 2020
[Immunotherapy for BRAF mutant metastatic melanoma.]Ernesto Rossi
Human Vaccines & Immunotherapeutics|May 18, 2022
Editorial of special focus on melanoma immunotherapyErnesto Rossi
Frontiers in Oncology|February 1, 2024
Editorial: Non-cutaneous melanoma: new therapeutic insightsErnesto Rossi, Richard D Carvajal
Journal for Immunotherapy of Cancer|July 24, 2020
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatmentErnesto Rossi, Giovanni Schinzari, Giampaolo Tortora
Human Vaccines & Immunotherapeutics|February 1, 2023
Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective studyErnesto Rossi, Luca Boldrini, Maria Grazia Maratta, et al.
Immunotherapy|October 19, 2021
Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case reportMariangela Massaccesi, Luca Boldrini, Angela Romano, et al.
Melanoma Research|October 28, 2017
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II studyGiovanni Schinzari, Ernesto Rossi, Alessandra Cassano, et al.
Dermatology (Basel, Switzerland)|April 17, 2024
Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and ImmunotherapyMaria Mannino, Pietro Sollena, Alessandro Di Stefani, et al.
Anticancer Research|September 6, 2017
First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) <i>Versus</i> 5-FU/LV (de Gramont Regimen)Giovanni Schinzari, Ernesto Rossi, Giuseppina Mambella, et al.
International Journal of Molecular Sciences|January 27, 2019
The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of CancerRossella Cianci, Laura Franza, Giovanni Schinzari, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Recenti Progressi in Medicina|December 28, 2020
[Immunotherapy for BRAF mutant metastatic melanoma.]Ernesto Rossi
Human Vaccines & Immunotherapeutics|May 18, 2022
Editorial of special focus on melanoma immunotherapyErnesto Rossi
Frontiers in Oncology|February 1, 2024
Editorial: Non-cutaneous melanoma: new therapeutic insightsErnesto Rossi, Richard D Carvajal
Journal for Immunotherapy of Cancer|July 24, 2020
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatmentErnesto Rossi, Giovanni Schinzari, Giampaolo Tortora
Human Vaccines & Immunotherapeutics|February 1, 2023
Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective studyErnesto Rossi, Luca Boldrini, Maria Grazia Maratta, et al.
Immunotherapy|October 19, 2021
Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case reportMariangela Massaccesi, Luca Boldrini, Angela Romano, et al.
Melanoma Research|October 28, 2017
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II studyGiovanni Schinzari, Ernesto Rossi, Alessandra Cassano, et al.
Dermatology (Basel, Switzerland)|April 17, 2024
Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and ImmunotherapyMaria Mannino, Pietro Sollena, Alessandro Di Stefani, et al.
Anticancer Research|September 6, 2017
First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) <i>Versus</i> 5-FU/LV (de Gramont Regimen)Giovanni Schinzari, Ernesto Rossi, Giuseppina Mambella, et al.
International Journal of Molecular Sciences|January 27, 2019
The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of CancerRossella Cianci, Laura Franza, Giovanni Schinzari, et al.
Pageof 9